期刊論文| 1. | Levin, R. C.、Klevorick, A. K.、Nelson, R. R.、Winter, S. G.(1987)。Appropriating the Returns From Industrial Research and Development。Brookings Papers on Economic Activity，1987(3)，783-831。   |
| 2. | Sharma, A.、Lacey, N.(2004)。Linking Product Development Outcomes to Market Valuation of the Firm: The Case of the US Pharmaceutical Industry。Journal of Product Innovation Management，21(5)，297-308。 |
| 3. | Arundel, A.、Kabla, I.(1998)。What percentage of innovations are patented? Empirical estimates for European firms。Research Policy，27(2)，127-141。 |
| 4. | Chen, Y.-S.、Chang, K.-C.(2010)。The relationship between a firm's patent quality and its market value: The case of US pharmaceutical industry。Technological Forecasting and Social Change，77(1)，20-33。 |
| 5. | Rao, S. M.(1996)。The Effect of Published Reports of Environmental Pollution on Stock Prices。Journal of Financial and Strategic Decisions，9(1)，25-32。 |
| 6. | Liu, Q.(2006)。How good is good news? Technology depth, book-to-market ratio, and innovative events。Journal of Accounting, Auditing and Finance，21(3)，293-321。 |
| 7. | Poitras, M.(2004)。The Impact of Macroeconomic Announcements on Stock Prices: In Search of State Dependence。Southern Economic Journal，70(3)，549-565。 |
| 8. | Slovin, M. B.、Sushka, M. E.、Bendeck, Y. M.(1991)。The intra-industry effects of going-private transactions。Journal of Finance，46(4)，1537-1550。 |
| 9. | Pérez-Rodríguez, J. V.、Valcárcel, B. G. L.(2012)。Do Product Innovation and News about the R&D Process Produce Large Price Changes and Overreaction? The Case Of Pharmaceutical Stock Prices。Applied Economics，44(17)，2217-2229。 |
| 10. | Mc Namara, P. M.、Baden-Fuller, C.(2007)。Shareholder returns and the exploration-exploitation dilemma: R&D announcements by biotechnology firms。Research Policy，36(4)，548-565。 |
| 11. | Paul, Steven M.、Mytelka, D. S.、Dunwiddie, C. T.、Persinger, C. C.、Munos, B. H.、Lindborg, S. R.、Schacht, A. L.(2010)。How to improve R&D productivity: The pharmaceutical industry's grand challenge。Nature Reviews Drug Discovery，9(3)，203-214。 |
| 12. | MacKinlay, A. Craig(1997)。Event Studies in Economics and Finance。Journal of Economic Literature，35(1)，13-39。 |
| 13. | Brown, Stephen J.、Warner, Jerold B.(1980)。Measuring security price performance。Journal of Financial Economics，8(3)，205-258。 |
| 14. | Bulow, Jeremy I.、Geanakoplos, John D.、Klemperer, Paul D.(1985)。Multimarket Oligopoly: Strategic Substitutes and Complements。Journal of Political Economy，93(3)，488-511。 |
| 15. | Abud, M. J.、Hall, B.、Helmers, C.(2015)。An empirical analysis of primary and secondary pharmaceutical patents in Chile。PLoS ONE，10(4)。 |
| 16. | Chong, C. R.、Sullivan, D. J. Jr.(2007)。New uses for old drugs。Nature，448(7154)，645-646。 |
| 17. | Filson, D.、Oweis, A.(2010)。The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry。Journal of Health Economics，29(4)，575-584。 |
| 18. | Han, J.-S.、Lee, S.-Y. T.(2013)。The impact of technology transfer contract on a firm's market value in Korea。The Journal of Technology Transfer，38(5)，651-674。 |
| 19. | Hwang, T. J.(2013)。Stock market returns and clinical trial results of investigational compounds: An event study analysis of large biopharmaceutical companies。PLoS ONE，8(8)。 |
| 20. | Kurov, A.、Sancetta, A.、Strasser, G.、Wolfe, M. H.(2019)。Price drift before US macroeconomic news: Private information about public announcements?。Journal of Financial & Quantitative Analysis，54(1)，449-479。 |
| 21. | Ledford, H.(2011)。Blockbuster drug bows out: Pharmaceutical industry anxiously struggles to retool as Lipitor patent expires。Nature，480(7375)，16-17。 |
| 22. | Lichtenberg, F. R.(2005)。The impact of new drug launches on longevity: Evidence from longitudinal, disease-level data from 52 countries, 1982-2001。International Journal of Health Care Finance & Economics，5(1)，47-73。 |
| 23. | Motohashi, K.(2007)。The changing autarky pharmaceutical R&D process: Causes and consequences of growing R&D collaboration in Japanese firms。International Journal of Technology Management，39(1/2)，33-48。 |
| 24. | Overgaard, C. B.、van den Broek, R. A.、Kim, J. H.、Detsky, A. S.(2000)。Biotechnology stock prices before public announcements: Evidence of insider trading?。Journal of Investigative Medicine，48(2)，118-124。 |
| 25. | Panattoni, L. E.(2011)。The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms。Journal of Health Economics，30(1)，126-145。 |
| 26. | Rothenstein, J. M.、Tomlinson, G.、Tannock, I. F.、Detsky, A. S.(2011)。Company stock prices before and after public announcements related to oncology drugs。Journal of the National Cancer Institute，103(20)，1507-1512。 |
| 27. | Sedighi, M.、Jahangirnia, H.、Gharakhani, M.、Farahani Fard, S.(2019)。A novel hybrid model for stock price forecasting based on metaheuristics and support vector machine。Data，4(2)。 |
| 28. | Stankevičienė, J.、Akelaitis, S.(2014)。Impact of public announcements on stock prices: The example of Lithuanian stock market considering values of stock prices。Economics & Business，26，107-112。 |
| 29. | Sternitzke, C.(2010)。Knowledge sources, patent protection, and commercialization of pharmaceutical innovations。Research Policy，39(6)，810-821。 |
| 30. | Xu, B.(2006)。R&D progress, stock price volatility, and post-announcement drift: An empirical investigation into biotech firms。Review of Quantitative Finance & Accounting，26(4)，391-408。 |
| 31. | Brown, Stephen J.、Warner, Jerold B.(1985)。Using Daily Stock Returns: The Case of Event Studies。Journal of Financial Economics，14(1)，3-31。 |